Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3670747 | 0.98 | ALDH1A1 (0.32) | ALDH1A1KDM4EHPGDGRM4CRHR1 | |
| SCHEMBL3681245 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL6531918 | 0.86 | — | — | |
| Bromide SCHEMBL15203878 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL713347 | 0.86 | — | — | |
| Iodide SCHEMBL15204070 | 0.86 | — | — | |
| SCHEMBL28381841 | 0.79 | CRHR1 (0.30) | CRHR1 | |
| Hydrochloric Acid SCHEMBL14574621 | 0.78 | HTR1A (0.31) | CRHR1 | |
| SCHEMBL18040436 | 0.78 | ALOX5 (0.37) | ALDH1A1KDM4EHPGDMAPTSMN1; SMN2 | |
| SCHEMBL13238426 | 0.76 | MAPT (0.39) | ALDH1A1HPGDCRHR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916227-A | Process for preparing perfuming intermediates | 弗门尼舍有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115003649-A | Process for the preparation of perfuming intermediates | 弗门尼舍有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-8829030-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2014-09-09 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-04-18 | — | — | US | disclosed |
| US-8357718-B2 | N-heterocyclyl- or cycloalkyl-N-(2-carboxy-5-aryl-3-thiophenyl)cycloalkanecarboxamides, e.g., 5-(3-fluorophenyl)-3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-thiophene-2-carboxylic acid; especially for prevention and treatment of HVC | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-01-22 | — | — | US | disclosed |
| EP-1569929-B9 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2011-09-14 | — | — | EP | disclosed |
| US-7906573-B2 | Crosslinked polycyclooctene | UNIVERSITY OF CONNECTICUT (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | disclosed |
| US-20100160522-A1 | CROSSLINKED POLYCYCLOOCTENE | MATHER PATRICK T | 2010-06-24 | — | — | US | disclosed |
| EP-1395257-A1 | MACROCYCLES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1351924-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1268450-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002100399-A1 | MACROCYCLES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100851-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
| US-20020128212-A1 | 14-membered macrolides derived from leucomycins | SILICON VALLEY BANK DBA SILICON VALLEY EAST | 2002-09-12 | — | — | US | disclosed |
| US-6440942-B1 | MODIFICATIONS TO ENHANCE ACID STABILITY AND PREVENT ANHYDRO FORMATION; ROXITHROMYCIN AND CLARITHROMYCIN; ACTIVE AGAINST MLS-RESISTANT STRAINS (MLS=MACROLIDES-LINCOSAMIDES-STREPTOGRAMINES) | ENANTA PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001092235-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | ALDH1A1 684/4885KDM4E 3220/4885HPGD 2916/4885 |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, ZYX, ZFX | ALDH1A1 1591/4885KDM4E 1505/4885HPGD 3391/4885 |
| US-20020128212-A1 | 14-membered macrolides derived from leucomycins | IL15, RPL21, RPL14 | ALDH1A1 4055/4885KDM4E 1381/4885HPGD 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.